Headline telemedicine funding numbers are mostly one specialist platform, and that concentration says a lot about where the category's thesis actually lives now.
Telemedicine funding looks broad from the outside. Break down where the money actually went this year and it collapses into a much narrower, specialty-specific story.
One platform, over a quarter of the category
In pure-play telemedicine funding between August 2025 and July 2026, the top 3 deals accounted for 52.59% of all disclosed capital, and Talkiatry alone represented 26.94% of that total, according to New Market Pitch.
Telemedicine has stopped being a standalone investment thesis and become a delivery layer attached to a specific specialty shortage.
Only one qualifying deal in the entire period went to a generic video-consultation platform; nearly everything else clustered around specialist telehealth, telepsychiatry, and infrastructure attached to a specific clinical supply problem, such as psychiatry, pediatrics, women's health, neurology or cardiometabolic care.
That concentration mirrors the pattern already showing up in behavioral health telehealth claims data, discussed in the final article of this issue, where one specialty dominates usage by a wide margin over every other category, suggesting funding is following utilisation rather than the other way around.
Generic telehealth stopped being fundable
A startup pitching generic "telehealth" today is competing for the one slice of the market investors have effectively stopped funding.
The money has moved decisively toward companies solving a specific clinical supply problem through virtual delivery, not companies offering virtual delivery as the product itself, and that distinction is easy to miss in a one-line pitch that still says "telehealth platform" without specifying which shortage it actually solves.
Who tries to repeat Talkiatry's playbook
Watch which other single-specialty telehealth platforms attempt to replicate Talkiatry's concentration in a different clinical shortage area next, whether that's a physician specialty with long wait times or a population currently underserved by in-person care.
That replication pattern, more than any new generic telehealth entrant, is where the next big funding story in this category is likely to come from, and pediatrics, neurology and cardiometabolic care, the categories the New Market Pitch data flags as the other clusters attracting specialist rounds, are the most likely candidates to watch first.
